National Institute for Infectious Diseases "L. Spallanzani" IRCCS
About National Institute for Infectious Diseases "L. Spallanzani" IRCCS
The Lazzaro Spallanzani National Institute for Infectious Diseases is an infectious disease hospital in the Italian city of Rome. The institute is named for the eighteenth-century Italian biologist Lazzaro Spallanzani. It is the Italian national reference center for Ebola patients.
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Gilead Sciences
4
Hendrik Streeck
1
Institut d'Investigació Biomèdica de Bellvitge
1
Tuberculosis Network European Trialsgroup
1
Clinical Trials at National Institute for Infectious Diseases "L. Spallanzani" IRCCS
During the past decade, National Institute for Infectious Diseases "L. Spallanzani" IRCCS conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 1 clinical trials were completed, i.e. on
average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
2010-04-01
2014-09-01
Completed
708
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF
2010-11-01
2014-10-01
Completed
482
Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
2011-02-01
2014-02-01
Completed
799
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
2011-11-01
2014-12-01
Completed
438
New Generation IGRA in Immunocompromised Individuals
2015-12-01
2019-12-01
Unknown status
2,000
Study to Assess Management and Outcomes of Hospitalised Patients With Complicated UTI (RESCUING)
2015-12-01
2016-08-01
Completed
1,028
Prospective Observational Cohort HIV & STI Study in Europe
2019-04-24
2022-08-22
Completed
3,593
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "National Institute for Infectious Diseases "L. Spallanzani" IRCCS"
#1 collaborator was "AiCuris Anti-infective Cures AG" with 1 trials as a collaborator, "Janssen, LP" with 1 trials as a collaborator, "Tel Aviv University" with 1 trials as a collaborator, "UMC Utrecht" with 1 trials as a collaborator and "University of Bristol" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were
collaborators in the rest 5 trials.
Clinical Trials Conditions at National Institute for Infectious Diseases "L. Spallanzani" IRCCS
According to Clinical.Site data, the most researched conditions in "National Institute for Infectious Diseases "L. Spallanzani" IRCCS" are
"HIV Infections" (3 trials), "HIV-1 Infection" (2 trials), "Acquired Immunodeficiency Syndrome" (1 trials), "Active Tuberculosis" (1 trials) and "Bacterial Resistance" (1 trials). Many other conditions were trialed in "National Institute for Infectious Diseases "L. Spallanzani" IRCCS" in a lesser frequency.
Clinical Trials Intervention Types at National Institute for Infectious Diseases "L. Spallanzani" IRCCS
Most popular intervention types in "National Institute for Infectious Diseases "L. Spallanzani" IRCCS" are "Drug" (4 trials) and "Behavioral" (1 trials). Other intervention types were less common.
The name of intervention was led by "FTC/RPV/TDF" (2 trials), "FTC/TDF" (2 trials), "PI" (2 trials), "RTV" (2 trials) and "Stribild" (2 trials). Other intervention names were less common.
Clinical Trials Genders at National Institute for Infectious Diseases "L. Spallanzani" IRCCS
The vast majority of trials in "National Institute for Infectious Diseases "L. Spallanzani" IRCCS" are
6 trials for "All" genders and 1 trials for "Male" genders.
Clinical Trials Status at National Institute for Infectious Diseases "L. Spallanzani" IRCCS
Currently, there are NaN active trials in "National Institute for Infectious Diseases "L. Spallanzani" IRCCS".
undefined are not yet recruiting,
undefined are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 6 completed trials in National Institute for Infectious Diseases "L. Spallanzani" IRCCS,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 4 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".
Departments of National Institute for Infectious Diseases "L. Spallanzani" IRCCS
National Institute for Infectious Diseases "L. Spallanzani" IRCCS has several departments that took part in Clinical trials: "Centro di Riferimento Oncologico - Unit of Medical Oncology" - 8 trials
Departments List
Name
City
Trials